PatentsDB

Antibodies against 6-sulfo-LacNac-positive human dendritic cells, and their use

US9487585B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9487585-B2
Application numberUS-201113814512-A
CountryUS
Kind codeB2
Filing dateAug 5, 2011
Priority dateAug 6, 2010
Publication dateNov 8, 2016
Grant dateNov 8, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to a composition which contains at least one anti-slan antibody and to its diagnostic and therapeutic use. The composition according to the invention comprises: a) at least one anti-slan antibody, b) at least one binding unit which binds to a co-stimulus binding to a co-stimulus-specific receptor on dendritic cells, thereby bringing about the modulation, preferably the activation, of said dendritic cells, and c) at least one antigen. The invention furthermore comprises anti-slan antibodies which include CDRs with the following sequences: variable region of the heavy chain: CDR1 (SEQ ID No. 1), CDR2 (SEQ ID No. 2), where Xaa is selected from among M, L, F, or I, preferably from among M or I, CDR3 (SEQ ID No. 5) and variable region of the light chain: CDR1 (SEQ ID No. 6), where Xaa is selected from among S, T, N, Q, H, K or R, preferably from among S or N, CDR2 (SEQ ID No. 9) and CDR3 (SEQ ID No. 10).

First claim

Opening claim text (preview).

What is claimed is: 1. A composition comprising a) at least one anti-slan antibody which binds specifically to 6-sulfo N-acetyl lactosamine (6-suldo LacNAc) of P-selectin glycoprotein ligand 1 (PSGL-1) on the surface of human dendritic cells, b) at least one binding unit which binds to a co-stimulus, wherein the co-stimulus binds to a receptor on dendritic cells that is specific for the co-stimulus, wherein the co-stimulus is selected from nucleic acid Toll-receptor ligands (TLR…

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

View patent family 44503823

External sources

Next steps

Free tools are coming soon. Tell us what you want to track and we'll notify you.

Get alerts for this patentView on Google Patents

Request deeper analysis

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9487585B2 cover?
The invention relates to a composition which contains at least one anti-slan antibody and to its diagnostic and therapeutic use. The composition according to the invention comprises: a) at least one anti-slan antibody, b) at least one binding unit which binds to a co-stimulus binding to a co-stimulus-specific receptor on dendritic cells, thereby bringing about the modulation, preferably the act…
Who is the assignee on this patent?
Bachmann Michael, Gräfe Daniel, Univ Dresden Tech
What technology area does this patent fall under?
Primary CPC classification C07K16/28. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).